DYN

15.4603.56%
JG

John G. Cox

CEO, President & Director

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 25, 2024. He also serves as Atlas Advisor at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2024. He served as Chairman of the Board at Minovia Therapeutics LTD and serves as its Executive Chairman. He joined Minovia Therapeutics LTD in February 2019. He served as Chief Executive Officer of Repertoire Immune Medicines, Inc. and served as its President and Director until January 2023. He served as Executive Vice President of Pharmaceutical Operations and Technology at Biogen Idec Ltd. Mr. Cox served as Executive Chairman of Torque Therapeutics Inc. Mr. Cox serves as Chief Executive Officer of Torque Therapeutics Inc. since October 2019 and has been its Director since January 2019. He served as Chief Executive Officer of Bioverativ Inc. from 2017 to 2019 and served as its Director until March 8, 2018. He served as an Executive Vice President of Therapeutic Operations of Biogen at Yumanity Therapeutics Inc. Mr. Cox has served as the Chief Executive Officer of Repertoire Immune Medicines since 2019. Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen Incorporated from 2016 until 2017. He served as the Chief Executive Officer of Hemophilia Business at Biogen Inc. since July 1, 2016 until February 4, 2017 and served as its Executive Vice President of Pharmaceutical Operations & Technology from 2015 to 2016 overseeing global manufacturing facilities, supply chain operations, technical development, quality and engineering and development and commercialization of Biogen's biosimilars business from June 2010 to July 01, 2016. He joined Biogen Idec in 2003 and served as its Senior Vice President of Global Manufacturing and Operations. He served senior operational roles at Covance Biotech and American Home Products Corporation, the Wyeth LLC subsidiary of Pfizer Inc. He held a number of senior operational roles at Diosynth Inc. where he worked in technology transfer, validation and purification. Mr. Cox focused on the same areas at Wyeth Corporation from 1993 to 2000. He served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Director of Manufacturing, Vice President of Manufacturing as well as General Manager of Biogen Idec's operations in Research Triangle Park, North Carolina. He served as Independent Director at Repligen Corporation from November 2013 to May 13, 2020 and had been its Member of Scientific Advisory Board since March 2016. He had been Independent Director of Sigilon Therapeutics, Inc. since May 7, 2019 until August 11, 2023. Mr. Cox received a B.S. in cell biology from California State University and a Master of Business Administration in Finance degree from the University of Michigan. He holds MS in Cellular Biology from California State University. He holds a B.S. in biology from Arizona State University.

Positions